Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02979392 | Phase I Study of TENPA in Advanced Solid Cancer | terminated | Phase 1 | 19 | Yung-Jue BangOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT01894243 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 5 | Sep 13, 2019 | clinicaltrials |
| NCT02894944 |
| Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer(Theragene) |
| completed |
| Phase 1 |
| 9 |
| Seoul National University HospitalOTHER |
| 1 |
| Sep 12, 2019 |
| clinicaltrials |
| NCT03081819 | A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer | completed | Phase 1 | 11 | Kyunghee University Medical CenterOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02250170 | Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor | completed | Phase 1 | 47 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2019 | clinicaltrials |
| NCT02734160 | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 | 37 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 5, 2019 | clinicaltrials |
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | completed | Phase 1 | 103 | PfizerINDUSTRY | 9 | Aug 2, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT03366064 | Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(Medi-NK) | completed | Phase 1 | 5 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT03322020 | Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer(ADEBAR) | completed | Phase 1 / Phase 2 | 30 | Asan Medical CenterOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT02248090 | AZD9496 First Time in Patients Ascending Dose Study | completed | Phase 1 | 45 | AstraZenecaINDUSTRY | 3 | Jun 24, 2019 | clinicaltrials |
| NCT02737228 | Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 24 | CrystalGenomics, Inc.INDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01212107 | A Phase 1 Study of LY2874455 in Participants With Advanced Cancer | completed | Phase 1 | 94 | Eli Lilly and CompanyINDUSTRY | 2 | Jun 12, 2019 | clinicaltrials |
| NCT02426723 | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | completed | Phase 1 | 25 | JW PharmaceuticalINDUSTRY | 2 | May 17, 2019 | clinicaltrials |
| NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 3 | Mar 25, 2019 | clinicaltrials |
| NCT03881878 | TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery | unknown | Phase 1 / Phase 2 | 67 | Samsung Medical CenterOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT02161770 | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 6 | Mar 8, 2019 | clinicaltrials |
| NCT02507427 | Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study) | completed | Phase 1 / Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00697632 | Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies | completed | Phase 1 | 180 | Mirati Therapeutics Inc.INDUSTRY | 3 | Feb 12, 2019 | clinicaltrials |
| NCT00946153 | Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 66 | Eisai Co., Ltd.INDUSTRY | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT03358849 | Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer | completed | Phase 1 | 9 | Yonsei UniversityOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03556436 | Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 | completed | Phase 1 | 24 | Yuhan CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT02963389 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients | completed | Phase 1 | 27 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT01764828 | BAY86-9766 Plus Gemcitabine Phase I Study in Asian | completed | Phase 1 | 23 | BayerINDUSTRY | 3 | Nov 1, 2018 | clinicaltrials |
| NCT03628131 | Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | completed | Phase 1 / Phase 2 | 105 | Puma Biotechnology, Inc.INDUSTRY | 11 | Sep 5, 2018 | clinicaltrials |
| NCT01602952 | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | completed | Phase 1 / Phase 2 | 85 | Il-Yang Pharm. Co., Ltd.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT02293850 | Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Oncolys BioPharma IncINDUSTRY | 2 | Aug 20, 2018 | clinicaltrials |
| NCT01911325 | Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 | 27 | Novartis PharmaceuticalsINDUSTRY | 8 | Aug 14, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT01458067 | A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 3 | Jul 24, 2018 | clinicaltrials |
| NCT01588145 | Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients | completed | Phase 1 / Phase 2 | 273 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Apr 24, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT00790816 | Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents | completed | Phase 1 | 500 | Novartis PharmaceuticalsINDUSTRY | 5 | Feb 28, 2018 | clinicaltrials |
| NCT01728311 | Open Label Study of BAY1082439 in Patients With Advanced Cancer | completed | Phase 1 | 60 | BayerINDUSTRY | 3 | Jan 30, 2018 | clinicaltrials |
| NCT02318394 | A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2018 | clinicaltrials |
| NCT03282825 | Clinical Study of Decitabine and Paclitaxel Combination Therapy | unknown | Phase 1 | 18 | Dong Wha Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02400788 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 179 | Yakult Honsha Co., LTDINDUSTRY | 2 | Jan 16, 2018 | clinicaltrials |
| NCT00650910 | Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer | completed | Phase 1 | 17 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT00849329 | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 3 | Nov 14, 2017 | clinicaltrials |
| NCT00483860 | A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function | completed | Phase 1 | 59 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials